Sophrosyne logo

Reducing the physical, psychological, and economic burden of alcohol and drug abuse

We are a clinical-stage company dedicated to transforming the management of substance abuse, with the potential for blockbuster opportunities. Our portfolio includes breakthrough therapies for Alcohol Use Disorder (AUD), built on a foundation of novel new chemical entities (NCEs) that leverage proven therapeutic mechanisms. With robust global patent protection extending through the 2040s - including composition of matter - we are well-positioned to lead innovation in this critical field.
WHY WE CREATED SOPHROSYNE

The Problem to Solve – AUD Causes Health, Economic, and Societal Havoc in the U.S. and Around the World

Woefully Inadequate Current Standard of Care

  • 3 very old, minimally effective, and toxic medications
  • Less than 10% of people with AUD receive any kind of treatment1
  • 1.6% receive any medication treatment2
  • 1 in 9 people achieve abstinence with psychosocial treatment3

Proven Target ALDH2

  • Disulfiram, requires careful screening, described as having a sledgehammer approach which yields unpredictable efficacy, is intolerable and risks dangerous side effects, with extremely poor long-term outcomes (90%+ relapse)4
  • Side effects ranging from nausea and GI consequences to serious adverse events, liver related toxicity and possible death all contribute to HCP dissatisfaction with current products
  • Oral formulations lead to more non-adherent behavior when patients intentionally or unintentionally miss their dose

Ideal New Therapeutics Option

  • A highly potent and surgical approach to reducing ALDH2.
  • Predictable patient efficacy
  • Patient safety and well tolerated for long-term use
  • Ability to use in combination wiht other drugs
  • Flexible usage administration to enable high adherence

Alcohol Addiction Alters The Brain

  • Genetic risk of ~50% for developing AUD5
  • Alcohol alters brain circuitry across all major neurotransmitter systems: dopamine, opioid, serotonin, glutamate, GABA, and acetylcholine (Ach)
  • Long-term changes in brain structure and function involve genetic and epigenetic changes that drive destructive ongoing drinking

Portfolio Projected to Achieve Superior Efficacy and Safety Plus Dosing Flexibility for Optimal Treatment Results

  • Predictably effictive - "surgical" approach to ALDH2 inhibition
  • Long-acting
  • Safe and well tolerated for long-term use
  • Flexible dosing enables individualizing optimal treatment protocol for sustained abstinence

Long ActingSOPH-150

Month 1
Month 7

MonthlySOPH-123

M 1
M 2
M 3

WeeklySOPH-110s

W 1
W 2
W 3
W 4
W 5
W 6
W 7
W 8
W 9
W 10
W 11
W 12
SOPH-110s Engineered to Specifically Target ALDH2 and Preclude Breakdown of Acetaldehyde flowchart
Robust Preclinical Efficacy - Evidence of SOPH-110S Inhibiting ALDH2 Activity at Low Doses

Interested in more information on partnership or licensing opportunities?

References:

  1. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics-z/alcohol-facts-and-statistics/alcohol-treatment-united-states?utm
  2. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.856938/full?utm
  3. Cognitive Behavioral Therapy (CBT), Motivational Interviewing (MI), 12-Step Facilitation. Source: Project MATCH Research Group, 1997-2003
  4. https://www.armsacres.com/blog/alcohol-relapse-statistics-and-facts?utm
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC5004749/?